Global Competition, Tech Transfer Traps, and Cost Reduction Realities with Alfred Sloan

 In this episode of Out of the Lab, host Nico sits down with 20-year cell and gene therapy expert Alfred Sloan to dissect the operational and capital constraints facing advanced therapy development today.

From the pressure to rapidly accelerate clinical timelines to the rising threat of global competition outcasting domestic manufacturing costs, Alfred breaks down why the industry must shift from isolated IP retention to scalable, repeatable manufacturing frameworks.

Key Discussion Points:

• The Scalability Gap: Why existing technologies fail to scale seamlessly from research to commercial production.

• Global Competition & Medical Tourism: How overseas government subsidies and collaborative models threaten to outpace US manufacturing within five years.

• Tech Transfer Traps: Why handing over a paper SOP to a CDMO leads to $100,000 run failures and how continuous technical support bridges the gap.

• Operational Cost Reduction: Navigating master service agreements, expediting fees, modular "widget" approaches, and standardizing assembly-line manufacturing.

  
  

Timestamps:

• 00:01:25 – Capital Constraints and Clinical Acceleration

• 00:03:27 – The Scalability Bottleneck Across Development Stages

• 00:06:28 – Breaking Down Knowledge Sharing and IP Barriers

• 00:11:36 – Global Competition, Government Subsidies, and Medical Tourism

• 00:16:43 – Operational Cost Reduction: Vendor Lock-In, Expediting Fees, and Modular Systems

• 00:20:50 – Tech Transfer Realities: The Limits of Paper SOPs and Scaling Microliters to Liters

• 00:26:26 – Asset Acquisition vs. Building from Scratch

• 00:33:27 – Supply Chain Vulnerabilities, Reagent Shortages, and Modular Platforms